Medicenna Therapeutics (TSX:MDNA) Price-to-Operating-Cash-Flow : (As of Apr. 25, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-25), Medicenna Therapeutics's share price is C$1.92. Medicenna Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.20. Hence, Medicenna Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Medicenna Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

TSX:MDNA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.7
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Medicenna Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was C$-0.06. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.20.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 6.00% per year.

During the past 9 years, Medicenna Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 26.70% per year. The lowest was -24.80% per year. And the median was -4.90% per year.

Medicenna Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Medicenna Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Price-to-Operating-Cash-Flow Chart

Medicenna Therapeutics Annual Data

Trend

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Medicenna Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Medicenna Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Medicenna Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medicenna Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Medicenna Therapeutics's Price-to-Operating-Cash-Flow falls into.

Medicenna Therapeutics Price-to-Operating-Cash-Flow Calculation

Medicenna Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.92	/	-0.197
	=

Medicenna Therapeutics's Share Price of today is C$1.92.
Medicenna Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.20.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Medicenna Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics (TSX:MDNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Medicenna Therapeutics (TSX:MDNA) Headlines

No Headlines